ABSTRACT
No disponible
Subject(s)
Humans , Male , Child , Adult , Aged , Pyomyositis/diagnosis , Pyomyositis/drug therapy , Pyomyositis/pathology , Escherichia coli , Escherichia coli/isolation & purification , Retrospective Studies , Hematologic Diseases/diagnosis , Hematologic Diseases/drug therapy , Hematologic Diseases/pathology , Hemic and Lymphatic Diseases/complications , Hemic and Lymphatic Diseases/drug therapy , Hemic and Lymphatic Diseases/pathology , Hematologic Neoplasms/epidemiology , Muscle, Skeletal , AbscessABSTRACT
MYC and BCL2 gene translocations and protein expression have recently demonstrated to be of prognostic significance in systemic diffuse large B-cell lymphoma (DLBCL). However, their role in primary central nervous system DLBCL (CNS-DLBCL) prognosis has been scarcely analyzed. We studied the immunophenotype, the status of the MYC, BCL2, and BCL6 genes and the clinical features of a series of 42 CNS-DLBCL and evaluated their prognostic significance. We found high MYC protein expression in 43% of cases, and this was associated with lower overall survival (OS). Cases with concurrent expression of MYC and BCL2 showed a lower OS, although the difference did not reach statistical significance. Translocations involving the MYC or BCL2 genes were not detected. The BCL6 gene was frequently translocated, but was unrelated to survival. We conclude that MYC protein expression detected by immunohistochemistry identifies a CNS-DLBCL subset with worse prognosis and may contribute to a more accurate risk stratification of CNS-DLBCL patients.
